[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US3742951A - Bandage for controlled release of vasodilators - Google Patents

Bandage for controlled release of vasodilators Download PDF

Info

Publication number
US3742951A
US3742951A US00169977A US3742951DA US3742951A US 3742951 A US3742951 A US 3742951A US 00169977 A US00169977 A US 00169977A US 3742951D A US3742951D A US 3742951DA US 3742951 A US3742951 A US 3742951A
Authority
US
United States
Prior art keywords
bandage
sensitive adhesive
pressure
release rate
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00169977A
Inventor
A Zaffaroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of US3742951A publication Critical patent/US3742951A/en
Publication of US3742951B1 publication Critical patent/US3742951B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Medical bandage for use in the continuous administration to circulation of controlled quantities of systemically active coronary vasodilators over a prolonged period of time by absorption through the external body skin or mucosa is comprised of a backing member, a pressure-sensitive adhesive coating, and a reservoir containing the drug confined within a wall member. The wall member is formed from drug release rate controlling material to continuously meter the flow of a therapeutically effective amount of the drug from the reservoir to the skin at a controlled and predetermined rate over a period of time.

Claims (19)

1. A medical bandage for the continuous administration to the skin or mucosa of controlled quantities of systemically active vasodilator drugs over a prolonged period of time by absorption through the external body skin or mucosa, said bandage comprising a laminate of (1) a backing member defining one face surface of the bandage; (2) a pressure-sensitive adhesive adapted for contact with the skin or mucosa, the external surface of said pressure-sensitive adhesive defining the other face surface of the bandage and, disposed between the face surfaces defined by (1) and (2); (3) at least one reservoir comprised of a systemically active vasodilator drug formulation confined within a wall member, said wall member being formed from drug release rate controlling material to continuously meter the flow of drug from the said reservoir to the skin or mucosa at a controlled and predetermined rate over a prolonged period of time.
2. The bandage as defined by claim 1, wherein said reservoir comprises a discrete, middle reservoir layer sandwiched between said backing member (1) and said pressure-sensitive adhesive (2).
3. The bandage as defined by claim 2, wherein the reservoir layer is comprised of a walled container having an interior chamber containing the systemically active vasodilator drug formulation.
4. The bandage as defined by claim 3, wherein only that portion of the walled container which is adapted to be brought contiguous with the skin or mucosa is formed from the drug release rate controlling material.
5. The bandage as defined by claim 2, wherein the reservoir layer is comprised of a matrix of the drug release rate controlling wall material, said matrix having the systemically active vasodilator drug formulation distributed therethrough.
6. The bandage as defined by claim 2, further comprising a solubility membrane (4) interposed between said reservoir layer and said pressure-sensitive adhesive (2).
7. The bandage as defined by claim 2, wherein one outer surface of the wall member comprising the reservoir layer also defines the said backing member (1).
8. The bandage as defined by claim 1, wherein said reservoir comprises a plurality of discrete microcapsules distributed throughout the said pressure sensitive adhesive.
9. The bandage as defined by claim 8, wherein each of said microcapsules is comprised of systemically active vasodilator drug formulation microencapsulated with the said drug release rate controlling wall material.
10. The bandage as defined by claim 8, wherein each of said microcapsules is comprised of a matrix of the drug release rate controlling wall material, said matrix having the systemically active vasodilator drug formulation distributed therethrough.
11. The bandage as defined by claim 1, wherein the pressure-sensitive adhesive is permeable to passage of the systemically active vasodilator drug formulation.
12. The bandage as defined by claim 1, wherein the vasodilator drug formulation comprises a pharmacologically acceptable solvent.
13. The bandage as defined by claim 1, wherein said drug release rate controlling material is silicone rubber.
14. The bandage as defined by claim 1, wherein said drug release rate controlling material is a hydrophilic polymer of an ester of an olefinic acid.
15. The bandage as defined by claim 1, wherein the pressure-sensitive adhesive is covered with a protective release coating.
16. The bandage as defined by claim 1, wherein the outer surface of the backing member is coated with a low adhesion backsize.
17. The bandage as defined by claim 1, wherein the vasodilator is nitroglycerin.
18. The bandage as defined by claim 1, wherein the organic nitrate vasodilator is present in an amount of from about 1 microgram to about 1 gram.
19. The method of effecting vasodilation in a mammalian organism, comprising direct application to the skin or mucosa of such organism, the bandage as defined by claim 1.
US00169977A 1971-08-09 1971-08-09 Bandage for controlled release of vasodilators Expired - Lifetime US3742951A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16997771A 1971-08-09 1971-08-09

Publications (2)

Publication Number Publication Date
US3742951A true US3742951A (en) 1973-07-03
US3742951B1 US3742951B1 (en) 1982-11-23

Family

ID=22617994

Family Applications (1)

Application Number Title Priority Date Filing Date
US00169977A Expired - Lifetime US3742951A (en) 1971-08-09 1971-08-09 Bandage for controlled release of vasodilators

Country Status (1)

Country Link
US (1) US3742951A (en)

Cited By (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886939A (en) * 1973-09-04 1975-06-03 Steve Boxer Device for alleviating muscular discomfort
US3896789A (en) * 1974-06-10 1975-07-29 Riker Laboratories Inc Retinoic acid dipensing pressure sensitive dermotological tape
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
JPS5315409A (en) * 1976-07-29 1978-02-13 Toray Ind Inc Preparation for slow release of bioactive substance
DE2647581A1 (en) * 1976-10-21 1978-04-27 Henkel Kgaa BLISTER PACK
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
JPS56125311A (en) * 1980-02-04 1981-10-01 Alza Corp Bandage for administering drug to skin
JPS56147632U (en) * 1980-04-04 1981-11-06
WO1982000005A1 (en) * 1980-06-26 1982-01-07 Key Pharma Polymeric diffusion matrix containing a vasodilator
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
JPS57116210U (en) * 1981-01-12 1982-07-19
DE3200369A1 (en) * 1981-01-08 1982-08-05 Nitto Electric Industrial Co., Ltd., Ibaraki, Osaka PHARMACEUTICAL PREPARATION
JPS57150503U (en) * 1981-03-17 1982-09-21
FR2508318A1 (en) * 1981-06-29 1982-12-31 Alza Corp BANDAGE FOR THE ADMINISTRATION OF A PHARMACEUTICAL SUBSTANCE
JPS58913A (en) * 1981-06-26 1983-01-06 Nitto Electric Ind Co Ltd Pharmaceutical preparation for topical application
WO1983000091A1 (en) * 1981-07-08 1983-01-20 Keith, Alec, Dell Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
WO1983000093A1 (en) * 1981-07-08 1983-01-20 Key Pharma Trinitroglycerol sustained release vehicles and preparation therefrom
WO1983000092A1 (en) * 1981-07-08 1983-01-20 Key Pharma Polymeric diffusion matrix containing propranolol
JPS58134020A (en) * 1982-02-04 1983-08-10 Nitto Electric Ind Co Ltd Pharmaceutical preparation
US4421737A (en) * 1980-03-25 1983-12-20 Nippon Kayaku Kabushiki Kaisha Pressure-sensitive adhesive tape or pressure-sensitive adhesive sheet containing nitroglycerin
JPS5948416A (en) * 1982-09-10 1984-03-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
US4455146A (en) * 1979-04-03 1984-06-19 Hisamitsu Pharmaceutical Co., Ltd. Novel plasters
US4460562A (en) * 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4460368A (en) * 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication system
US4460370A (en) * 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication application cell
FR2542998A1 (en) * 1983-03-24 1984-09-28 Rhone Poulenc Sante NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE
US4482534A (en) * 1980-12-16 1984-11-13 Forest Laboratories, Inc. Nitroglycerin preparations
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4486193A (en) * 1981-07-22 1984-12-04 Alza Corporation Method for treating ischemic conditions by administering drug by two routes
EP0150428A2 (en) * 1983-12-28 1985-08-07 Bayer Ag Delivery system for an active substance
EP0150426A2 (en) * 1983-12-28 1985-08-07 Bayer Ag Delivery system for an active substance
US4556056A (en) * 1977-06-03 1985-12-03 Max-Planck-Gesellschaft Zur Forderung Der/Wissenschaften E.V. Transparent fluid bandage material and the preparation and use thereof
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4588580A (en) * 1984-07-23 1986-05-13 Alza Corporation Transdermal administration of fentanyl and device therefor
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4605399A (en) * 1984-12-04 1986-08-12 Complex, Inc. Transdermal infusion device
US4614787A (en) * 1984-11-13 1986-09-30 Thermedics, Inc. Drug dispensing wound dressing
US4631227A (en) * 1982-12-08 1986-12-23 Kenji Nakamura Toilet article
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
WO1987001291A1 (en) * 1985-08-30 1987-03-12 Rutgers, The State University Of New Jersey Novel transdermal anti-anginal pharmaceutical dosage unit and process for its administration
WO1987001935A1 (en) * 1985-10-03 1987-04-09 Rajadhyaksha Vithal J Transdermal and systemic preparation and method
US4661105A (en) * 1981-06-29 1987-04-28 Alza Corporation Medical bandage for administering vasodilator drug
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
EP0241806A1 (en) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4704119A (en) * 1983-02-03 1987-11-03 Alza Corporation Method comprising transdermal and buccal treatment of angina
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4727868A (en) * 1984-11-13 1988-03-01 Thermedics, Inc. Anisotropic wound dressing
US4738670A (en) * 1984-03-13 1988-04-19 Bayer Aktiengesellschaft Medicinal plasters
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
EP0273004A2 (en) * 1986-11-20 1988-06-29 Ciba-Geigy Ag User-activated therapeutical system
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4776850A (en) * 1985-05-24 1988-10-11 Beiersdorf Aktiengesellschaft Nitrate-containing plaster
US4787888A (en) * 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
EP0301424A2 (en) * 1987-07-24 1989-02-01 Fujisawa Pharmaceutical Co., Ltd. Sustained-release percutaneous preparations
US4812313A (en) * 1981-06-29 1989-03-14 Alza Corporation Method for lessening the incidence of anginal attacks
US4822617A (en) * 1983-01-18 1989-04-18 Elan Corporation P.L.C. Drug delivery device
US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4830856A (en) * 1987-01-27 1989-05-16 Peppers James M Chelation product
US4834979A (en) * 1981-06-29 1989-05-30 Alza Corporation Medical bandage for administering beneficial drug
US4836217A (en) * 1984-10-01 1989-06-06 Fischer Torkel I Hypersensitivity test means
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4844903A (en) * 1986-11-07 1989-07-04 Mepha Ag Process for the production of an adhesive plaster
US4846826A (en) * 1981-07-22 1989-07-11 Alza Corporation Method for treating ischemic conditions
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
USRE32991E (en) * 1984-11-13 1989-07-18 Thermedics, Inc. Drug dispensing wound dressing
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4880690A (en) * 1984-11-13 1989-11-14 Thermedics, Inc. Perfume patch
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4954344A (en) * 1981-06-29 1990-09-04 Alza Corporation Method for treating nocturnal angina
US4959208A (en) * 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4997655A (en) * 1987-06-22 1991-03-05 Biogal Gyogyszergyar Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5008111A (en) * 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US5035886A (en) * 1987-10-19 1991-07-30 Ppg Industries, Inc. Active agent delivery device
US5035894A (en) * 1987-10-15 1991-07-30 Dow Corning Corporation Controlled release compositions and transdermal drug delivery device
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5147339A (en) * 1987-09-22 1992-09-15 Coloplast A/S Dressing material for the treatment of wounds, and corpuscles for use in the production thereof
US5151271A (en) * 1981-08-27 1992-09-29 Nitti Electric Industrial Co., Ltd. Pressure-sensitively adhering composite medicinal preparation
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5186938A (en) * 1984-07-24 1993-02-16 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5268179A (en) * 1992-02-14 1993-12-07 Ciba-Geigy Corporation Ultrasonically sealed transdermal drug delivery systems
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5284660A (en) * 1986-06-13 1994-02-08 Alza Corporation Delayed onset transdermal delivery device
DE4301781A1 (en) * 1993-01-23 1994-07-28 Lohmann Therapie Syst Lts Patch containing nitroglycerin, process for its production and use
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
WO1994026270A1 (en) * 1993-05-06 1994-11-24 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic systems for the administration of serotonin agonists
WO1994027536A1 (en) * 1993-05-28 1994-12-08 Vericade, Inc. Condom with transdermal vasodilator
US5402777A (en) * 1991-06-28 1995-04-04 Alza Corporation Methods and devices for facilitated non-invasive oxygen monitoring
US5523094A (en) * 1992-08-05 1996-06-04 Synthelabo Transdermal pharmaceutical composition
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5643905A (en) * 1993-01-23 1997-07-01 Therapie-System Gmbh & Co., Kg Pharmaceutical formulation for the treatment of nicotine dependence
US5668143A (en) * 1993-11-29 1997-09-16 Merrell Pharmaceuticals Inc. Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1 action
US5684017A (en) * 1993-11-29 1997-11-04 Merrell Pharmaceuticals Inc. Benzenesulfonylimine derivatives as inhibitors of IL-1 action
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US5798347A (en) * 1993-01-19 1998-08-25 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5861170A (en) * 1991-12-20 1999-01-19 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Acetylsalicyclic acid-containing transdermal application system for antithrombotic therapy
US5912009A (en) * 1996-10-30 1999-06-15 Theratech, Inc. Fatty acid esters of glycolic acid and its salts
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
US6432940B1 (en) 1998-06-11 2002-08-13 Endorecherche, Inc. Uses for androst-5-ene-3β, 17β-diol
US6461596B1 (en) * 1997-02-18 2002-10-08 Andrea Taylor Composition and method for promoting hair growth
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6469227B1 (en) 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US6548510B1 (en) 1999-02-19 2003-04-15 Lts Lohmann Therapie Systeme Ag Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence
US20030181516A1 (en) * 2002-03-19 2003-09-25 Krylov Boris Vladimirovich Substance with sedative effect
US6627631B1 (en) * 1999-02-19 2003-09-30 Lts Lohmann Therapie-Systeme Ag Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
US20030212094A1 (en) * 2000-02-29 2003-11-13 Haruko Yamabe Novel cyclic amide derivatives
US20030215528A1 (en) * 2000-04-26 2003-11-20 Queens University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20030220632A1 (en) * 2002-05-23 2003-11-27 Wolfgang Strasser Method of using gel sheets for laser treatment
US20040006134A1 (en) * 2002-02-15 2004-01-08 Endorecherche, Inc. Antiandrogenic biphenyls
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
US20040116406A1 (en) * 2001-04-24 2004-06-17 Klaus Opitz Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
US20040132751A1 (en) * 2001-04-24 2004-07-08 Klaus Opitz Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
US20040167145A1 (en) * 2001-07-12 2004-08-26 Klaus Opitz Active ingredient combination for the pharmacological therapy of nicotine dependence
WO2004075933A2 (en) * 2003-02-26 2004-09-10 Lavipharm S.A. Devices for releasing volatile substances and methods of producing the devices
US20040192683A1 (en) * 2001-06-18 2004-09-30 Joachim Moormann Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments
US20040260253A1 (en) * 2003-06-18 2004-12-23 Rosati Coni F. Method and apparatus for supplying gas to an area
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US20050053647A1 (en) * 1999-05-21 2005-03-10 Rudolf Matusch Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
US20050197300A1 (en) * 1997-06-23 2005-09-08 Cellegy Pharmaceuticals Inc. Microdose therapy
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US20060199866A1 (en) * 2003-04-25 2006-09-07 Joachim Moormann Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse
US20060200100A1 (en) * 2003-06-18 2006-09-07 Rosati Coni F Method and apparatus for supplying gas to an area
WO2006133567A1 (en) 2005-06-17 2006-12-21 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
EP1749533A1 (en) 1997-10-28 2007-02-07 Winthrop-University Hospital Metal/thiol biocides
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
WO2007084266A2 (en) * 2006-01-19 2007-07-26 Dow Corning Corporation Silicone adhesive for adhesion to wet surfaces
US20070231401A1 (en) * 2005-09-27 2007-10-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
WO2008109124A1 (en) * 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
WO2008124922A1 (en) 2007-04-12 2008-10-23 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2002826A1 (en) 2000-11-16 2008-12-17 Euro-Celtique S.A. Titratable dosage transdermal delivery system
WO2009035818A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2087892A2 (en) 1999-07-01 2009-08-12 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating age associated learning and mental disorders
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US20100241219A1 (en) * 2005-06-20 2010-09-23 Abbeymoor Medical , Inc Medicament delivery article, accessory & system
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
WO2011139765A2 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
US20130018335A1 (en) * 2010-01-14 2013-01-17 Laboratoires Urgo Novel bandage including agglomerates of particles suitable for rapidly gelling or solubilising
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
WO2013148701A1 (en) 2012-03-26 2013-10-03 Golden Biotechnology Corporation Methods and compositions for treating arteriosclerotic vascular diseases
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying, and managing bone cancer pain
WO2014081675A1 (en) 2012-11-21 2014-05-30 Golden Biotechnology Corporation Methods and compositions for treating neurodegenerative diseases
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF DIABETIS
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2015089634A1 (en) 2013-12-19 2015-06-25 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
WO2015138919A1 (en) 2014-03-14 2015-09-17 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2016086063A1 (en) 2014-11-25 2016-06-02 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
WO2017197240A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
WO2019023420A1 (en) * 2017-07-26 2019-01-31 Dubois Brian R Devices and methods for treating epistaxis
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US10336738B2 (en) 2010-08-27 2019-07-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
US11590265B2 (en) 2015-02-23 2023-02-28 Biotissue Holdings Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
US11707492B2 (en) 2016-01-29 2023-07-25 Biotissue Holdings Inc. Fetal support tissue products and methods of use
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
US12145913B2 (en) 2021-04-19 2024-11-19 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122B1 (en) * 1969-04-01 1982-11-23

Cited By (429)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886939A (en) * 1973-09-04 1975-06-03 Steve Boxer Device for alleviating muscular discomfort
US4039653A (en) * 1974-01-23 1977-08-02 Defoney, Brenman, Mayes & Baron Long-acting articles for oral delivery and process
US3896789A (en) * 1974-06-10 1975-07-29 Riker Laboratories Inc Retinoic acid dipensing pressure sensitive dermotological tape
US3948263A (en) * 1974-08-14 1976-04-06 Minnesota Mining And Manufacturing Company Ballistic animal implant
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
JPS5315409A (en) * 1976-07-29 1978-02-13 Toray Ind Inc Preparation for slow release of bioactive substance
DE2647581A1 (en) * 1976-10-21 1978-04-27 Henkel Kgaa BLISTER PACK
US4556056A (en) * 1977-06-03 1985-12-03 Max-Planck-Gesellschaft Zur Forderung Der/Wissenschaften E.V. Transparent fluid bandage material and the preparation and use thereof
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4291014A (en) * 1979-01-11 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing estradiol diacetate
US4455146A (en) * 1979-04-03 1984-06-19 Hisamitsu Pharmaceutical Co., Ltd. Novel plasters
US4292303A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing clonidine
US4292302A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing terbutaline
US4294820A (en) * 1979-08-14 1981-10-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylephrine
US4289749A (en) * 1979-08-14 1981-09-15 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing phenylpropanolamine
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4292301A (en) * 1979-08-14 1981-09-29 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing ephedrine
JPS56125311A (en) * 1980-02-04 1981-10-01 Alza Corp Bandage for administering drug to skin
JPS6055044B2 (en) * 1980-02-04 1985-12-03 アルザ・コ−ポレ−シヨン Bandages for administering drugs to the skin
US4421737A (en) * 1980-03-25 1983-12-20 Nippon Kayaku Kabushiki Kaisha Pressure-sensitive adhesive tape or pressure-sensitive adhesive sheet containing nitroglycerin
JPS56147632U (en) * 1980-04-04 1981-11-06
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
WO1982000005A1 (en) * 1980-06-26 1982-01-07 Key Pharma Polymeric diffusion matrix containing a vasodilator
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4482534A (en) * 1980-12-16 1984-11-13 Forest Laboratories, Inc. Nitroglycerin preparations
DE3200369A1 (en) * 1981-01-08 1982-08-05 Nitto Electric Industrial Co., Ltd., Ibaraki, Osaka PHARMACEUTICAL PREPARATION
US4420470A (en) * 1981-01-08 1983-12-13 Nitto Electric Industrial Co., Ltd. Percutaneous absorption type pharmaceutical preparation of isosorbide dinitrate or pentaerythritol tetranitrate in pressure-sensitive laminate
JPS57116210U (en) * 1981-01-12 1982-07-19
JPS57150503U (en) * 1981-03-17 1982-09-21
JPS58913A (en) * 1981-06-26 1983-01-06 Nitto Electric Ind Co Ltd Pharmaceutical preparation for topical application
JPS5822057A (en) * 1981-06-29 1983-02-09 アルザ・コ−ポレ−シヨン Treating system by new bandage
US4849226A (en) * 1981-06-29 1989-07-18 Alza Corporation Method for increasing oxygen supply by administering vasodilator
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
FR2508318A1 (en) * 1981-06-29 1982-12-31 Alza Corp BANDAGE FOR THE ADMINISTRATION OF A PHARMACEUTICAL SUBSTANCE
US4834979A (en) * 1981-06-29 1989-05-30 Alza Corporation Medical bandage for administering beneficial drug
AT395815B (en) * 1981-06-29 1993-03-25 Alza Corp THERAPEUTIC DELIVERY SYSTEM FOR THE ADMINISTRATION OF AN ACTIVE SUBSTANCE THROUGH THE SKIN
US4661105A (en) * 1981-06-29 1987-04-28 Alza Corporation Medical bandage for administering vasodilator drug
US4812313A (en) * 1981-06-29 1989-03-14 Alza Corporation Method for lessening the incidence of anginal attacks
US4954344A (en) * 1981-06-29 1990-09-04 Alza Corporation Method for treating nocturnal angina
WO1983000091A1 (en) * 1981-07-08 1983-01-20 Keith, Alec, Dell Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile
WO1983000093A1 (en) * 1981-07-08 1983-01-20 Key Pharma Trinitroglycerol sustained release vehicles and preparation therefrom
WO1983000092A1 (en) * 1981-07-08 1983-01-20 Key Pharma Polymeric diffusion matrix containing propranolol
US4486193A (en) * 1981-07-22 1984-12-04 Alza Corporation Method for treating ischemic conditions by administering drug by two routes
US4846826A (en) * 1981-07-22 1989-07-11 Alza Corporation Method for treating ischemic conditions
US5151271A (en) * 1981-08-27 1992-09-29 Nitti Electric Industrial Co., Ltd. Pressure-sensitively adhering composite medicinal preparation
US4460368A (en) * 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication system
US4460370A (en) * 1981-10-29 1984-07-17 Almedco, Inc. Trans-dermal medication application cell
US4460562A (en) * 1982-01-06 1984-07-17 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
US4482533A (en) * 1982-01-11 1984-11-13 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing propranolol
JPS58134020A (en) * 1982-02-04 1983-08-10 Nitto Electric Ind Co Ltd Pharmaceutical preparation
JPH0150203B2 (en) * 1982-09-10 1989-10-27 Nitto Denko Corp
US4594240A (en) * 1982-09-10 1986-06-10 Teikoku Seiyaku Kabushiki Kaisha Sheet-shape adhesive preparation
US4767787A (en) * 1982-09-10 1988-08-30 Kaken Pharmaceutical Co., Ltd. Sheet-shape adhesive preparation
JPS5948416A (en) * 1982-09-10 1984-03-19 Nitto Electric Ind Co Ltd Pharmaceutical preparation
US4631227A (en) * 1982-12-08 1986-12-23 Kenji Nakamura Toilet article
US4822617A (en) * 1983-01-18 1989-04-18 Elan Corporation P.L.C. Drug delivery device
US4704119A (en) * 1983-02-03 1987-11-03 Alza Corporation Method comprising transdermal and buccal treatment of angina
FR2542998A1 (en) * 1983-03-24 1984-09-28 Rhone Poulenc Sante NEW TRANSDERMAL FORM OF ISOSORBIDE DINITRATE
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
EP0150428A2 (en) * 1983-12-28 1985-08-07 Bayer Ag Delivery system for an active substance
US4661104A (en) * 1983-12-28 1987-04-28 Bayer Aktiengesellschaft Active compound release systems
EP0150428A3 (en) * 1983-12-28 1986-01-15 Bayer Ag Delivery system for an active substance
EP0150426A3 (en) * 1983-12-28 1986-01-15 Bayer Ag Delivery system for an active substance
US4627852A (en) * 1983-12-28 1986-12-09 Bayer Aktiengesellschaft Active compound release systems
EP0150426A2 (en) * 1983-12-28 1985-08-07 Bayer Ag Delivery system for an active substance
US4738670A (en) * 1984-03-13 1988-04-19 Bayer Aktiengesellschaft Medicinal plasters
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4588580A (en) * 1984-07-23 1986-05-13 Alza Corporation Transdermal administration of fentanyl and device therefor
US5186938A (en) * 1984-07-24 1993-02-16 Key Pharmaceuticals, Inc. Adhesive transdermal dosage layer
US4836217A (en) * 1984-10-01 1989-06-06 Fischer Torkel I Hypersensitivity test means
US4824676A (en) * 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US5008111A (en) * 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
USRE32991E (en) * 1984-11-13 1989-07-18 Thermedics, Inc. Drug dispensing wound dressing
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
US4751133A (en) * 1984-11-13 1988-06-14 Thermedics, Inc. Medical patches and processes for producing same
US4614787A (en) * 1984-11-13 1986-09-30 Thermedics, Inc. Drug dispensing wound dressing
US4880690A (en) * 1984-11-13 1989-11-14 Thermedics, Inc. Perfume patch
US4727868A (en) * 1984-11-13 1988-03-01 Thermedics, Inc. Anisotropic wound dressing
US4605399A (en) * 1984-12-04 1986-08-12 Complex, Inc. Transdermal infusion device
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4751087A (en) * 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4776850A (en) * 1985-05-24 1988-10-11 Beiersdorf Aktiengesellschaft Nitrate-containing plaster
WO1987000042A1 (en) * 1985-07-02 1987-01-15 Rutgers, The State University Of New Jersey Transdermal verapamil delivery device
WO1987001291A1 (en) * 1985-08-30 1987-03-12 Rutgers, The State University Of New Jersey Novel transdermal anti-anginal pharmaceutical dosage unit and process for its administration
WO1987001935A1 (en) * 1985-10-03 1987-04-09 Rajadhyaksha Vithal J Transdermal and systemic preparation and method
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
AU599619B2 (en) * 1985-12-17 1990-07-26 Novartis Ag Multicompartmentalized dermal and transdermal patches
US5204339A (en) * 1986-01-31 1993-04-20 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US5034386A (en) * 1986-01-31 1991-07-23 Whitby Research, Inc. Methods for administration using 1-substituted azacycloalkanes
US4743249A (en) * 1986-02-14 1988-05-10 Ciba-Geigy Corp. Dermal and transdermal patches having a discontinuous pattern adhesive layer
EP0241806A1 (en) * 1986-04-14 1987-10-21 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4749574A (en) * 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US5284660A (en) * 1986-06-13 1994-02-08 Alza Corporation Delayed onset transdermal delivery device
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US5342623A (en) * 1986-09-12 1994-08-30 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4844903A (en) * 1986-11-07 1989-07-04 Mepha Ag Process for the production of an adhesive plaster
EP0273004A3 (en) * 1986-11-20 1988-07-13 Ciba-Geigy Ag User-activated therapeutical system
EP0273004A2 (en) * 1986-11-20 1988-06-29 Ciba-Geigy Ag User-activated therapeutical system
US4917688A (en) * 1987-01-14 1990-04-17 Nelson Research & Development Co. Bandage for transdermal delivery of systemically-active drug
US4830856A (en) * 1987-01-27 1989-05-16 Peppers James M Chelation product
US4787888A (en) * 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US4997655A (en) * 1987-06-22 1991-03-05 Biogal Gyogyszergyar Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
EP0301424A2 (en) * 1987-07-24 1989-02-01 Fujisawa Pharmaceutical Co., Ltd. Sustained-release percutaneous preparations
US4889721A (en) * 1987-07-24 1989-12-26 Fujisawa Pharmaceutical Co., Ltd. Sustained-release percutaneous preparations
EP0301424A3 (en) * 1987-07-24 1989-07-12 Fujisawa Pharmaceutical Co., Ltd. Sustained-release percutaneous preparations
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US5147339A (en) * 1987-09-22 1992-09-15 Coloplast A/S Dressing material for the treatment of wounds, and corpuscles for use in the production thereof
US4920101A (en) * 1987-09-30 1990-04-24 Nelson Research & Development Co. Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5035894A (en) * 1987-10-15 1991-07-30 Dow Corning Corporation Controlled release compositions and transdermal drug delivery device
US4898920A (en) * 1987-10-15 1990-02-06 Dow Corning Corporation Adhesive compositions, controlled release compositions and transdermal delivery device
US5035886A (en) * 1987-10-19 1991-07-30 Ppg Industries, Inc. Active agent delivery device
US4959208A (en) * 1987-10-19 1990-09-25 Ppg Industries, Inc. Active agent delivery device
US5071645A (en) * 1987-10-19 1991-12-10 Ppg Industries, Inc. Process of producing an active agent delivery device
USRE39588E1 (en) 1987-11-09 2007-04-24 Alza Corporation Transdermal drug delivery device
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5633008A (en) * 1988-06-14 1997-05-27 Osborne; James L. Method of administering nicotine transdermally
US6165497A (en) * 1988-06-14 2000-12-26 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5328453A (en) * 1988-12-21 1994-07-12 Drug Delivery Systems Inc. Method for enhancing transdermal drug delivery of electrical drug applicators
US4985016A (en) * 1989-02-15 1991-01-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4969871A (en) * 1989-02-15 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent
US5250028A (en) * 1989-02-15 1993-10-05 Alza Corporation Intravenous system for delivering a beneficial agent using permeability enhancers
US5160320A (en) * 1989-02-15 1992-11-03 Alza Corporation Intravenous system for delivering a beneficial agent
US5045059A (en) * 1989-02-15 1991-09-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5173302A (en) * 1990-09-28 1992-12-22 Medtronic, Inc. Hydrophilic pressure sensitive adhesive for topical administration of hydrophobic drugs
US5837280A (en) * 1990-11-28 1998-11-17 Sano Corporation Transdermal administration of azapirones
US5817331A (en) * 1990-11-28 1998-10-06 Sano Corporation Transdermal administration of azapirones
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5402777A (en) * 1991-06-28 1995-04-04 Alza Corporation Methods and devices for facilitated non-invasive oxygen monitoring
US5273755A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset
US5273756A (en) * 1991-08-23 1993-12-28 Cygnus Therapeutic Systems Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset
US5234690A (en) * 1991-08-23 1993-08-10 Cygnus Therapeutic Systems Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset
US5861170A (en) * 1991-12-20 1999-01-19 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Acetylsalicyclic acid-containing transdermal application system for antithrombotic therapy
US5268179A (en) * 1992-02-14 1993-12-07 Ciba-Geigy Corporation Ultrasonically sealed transdermal drug delivery systems
US5523094A (en) * 1992-08-05 1996-06-04 Synthelabo Transdermal pharmaceutical composition
US5807849A (en) * 1993-01-19 1998-09-15 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5872114A (en) * 1993-01-19 1999-02-16 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5780460A (en) * 1993-01-19 1998-07-14 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5948434A (en) * 1993-01-19 1999-09-07 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5798347A (en) * 1993-01-19 1998-08-25 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5854229A (en) * 1993-01-19 1998-12-29 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5728688A (en) * 1993-01-19 1998-03-17 Endoreoherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5843932A (en) * 1993-01-19 1998-12-01 Endorcaherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5955455A (en) * 1993-01-19 1999-09-21 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5922700A (en) * 1993-01-19 1999-07-13 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5837700A (en) * 1993-01-19 1998-11-17 Endorecherche, Inc. Therapeutic methods and delivery systems utilizing sex steroid precursors
US5824671A (en) * 1993-01-19 1998-10-20 Endorecherche Inc Therapeutic methods and delivery systems utilizing sex steroid precursors
DE4301781A1 (en) * 1993-01-23 1994-07-28 Lohmann Therapie Syst Lts Patch containing nitroglycerin, process for its production and use
US5670164A (en) * 1993-01-23 1997-09-23 Lts Lohmann Therapie-Systeme Bmgh & Co., Kg Nitroglycerin-containing patch, a process for the production and the use thereof
US5643905A (en) * 1993-01-23 1997-07-01 Therapie-System Gmbh & Co., Kg Pharmaceutical formulation for the treatment of nicotine dependence
US5807571A (en) * 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
WO1994026270A1 (en) * 1993-05-06 1994-11-24 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic systems for the administration of serotonin agonists
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
WO1994027536A1 (en) * 1993-05-28 1994-12-08 Vericade, Inc. Condom with transdermal vasodilator
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
US5684017A (en) * 1993-11-29 1997-11-04 Merrell Pharmaceuticals Inc. Benzenesulfonylimine derivatives as inhibitors of IL-1 action
US5668143A (en) * 1993-11-29 1997-09-16 Merrell Pharmaceuticals Inc. Heterocyclic benzenesulfonylimine derivatives as inhibitors of IL-1 action
US5939095A (en) * 1993-12-10 1999-08-17 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman
US6096333A (en) * 1994-03-30 2000-08-01 Lectec Corporation Method of forming adhesive patch for applying medication to the skin
US5536263A (en) * 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5741510A (en) * 1994-03-30 1998-04-21 Lectec Corporation Adhesive patch for applying analgesic medication to the skin
US6096334A (en) * 1994-03-30 2000-08-01 Lectec Corporation Adhesive patch for applying medication to the skin and method
US5612382A (en) * 1994-07-15 1997-03-18 Frances B. Fike Composition for percutaneous absorption of pharmaceutically active ingredients
US5741511A (en) * 1995-04-12 1998-04-21 Sam Yang Co., Ltd. Transdermal drug delivery device for treating erectile dysfunction
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US20040081684A1 (en) * 1996-02-19 2004-04-29 Monash University Topical delivery of antifungal agents
EP1674068A1 (en) 1996-02-19 2006-06-28 Acrux DDS Pty Ltd Dermal penetration enhancers and drug delivery systems involving same
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US5912009A (en) * 1996-10-30 1999-06-15 Theratech, Inc. Fatty acid esters of glycolic acid and its salts
US5952000A (en) * 1996-10-30 1999-09-14 Theratech, Inc. Fatty acid esters of lactic acid salts as permeation enhancers
US6461596B1 (en) * 1997-02-18 2002-10-08 Andrea Taylor Composition and method for promoting hair growth
US7393825B2 (en) * 1997-06-23 2008-07-01 Strakan International Limited Microdose therapy
US20050197300A1 (en) * 1997-06-23 2005-09-08 Cellegy Pharmaceuticals Inc. Microdose therapy
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
EP1749533A1 (en) 1997-10-28 2007-02-07 Winthrop-University Hospital Metal/thiol biocides
US6995150B2 (en) 1998-06-11 2006-02-07 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US20040157812A1 (en) * 1998-06-11 2004-08-12 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6964955B2 (en) 1998-06-11 2005-11-15 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US8389548B2 (en) 1998-06-11 2013-03-05 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187966A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6432940B1 (en) 1998-06-11 2002-08-13 Endorecherche, Inc. Uses for androst-5-ene-3β, 17β-diol
US20080161277A1 (en) * 1998-06-11 2008-07-03 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6670346B1 (en) 1998-06-11 2003-12-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US8188066B2 (en) 1998-06-11 2012-05-29 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187968A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
US20070027122A1 (en) * 1998-06-11 2007-02-01 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20070027123A1 (en) * 1998-06-11 2007-02-01 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187967A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US7429576B2 (en) 1998-06-11 2008-09-30 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
EP1731157A2 (en) 1998-06-11 2006-12-13 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US20020187965A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
EP2399582A1 (en) 1998-06-11 2011-12-28 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
EP2386305A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
EP2386304A2 (en) 1998-06-11 2011-11-16 Endorecherche Inc. Selective Estrogen Receptor Modulator in Combination With Dehydroepiandrosterone (DHEA) or Analogues
US7884092B2 (en) 1998-06-11 2011-02-08 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6884795B2 (en) 1998-06-11 2005-04-26 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3β, 17β-diol
US7943603B2 (en) 1998-06-11 2011-05-17 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US20020187970A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-DIOL
US20020187963A1 (en) * 1998-06-11 2002-12-12 Endorecherche, Inc. Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
US6627631B1 (en) * 1999-02-19 2003-09-30 Lts Lohmann Therapie-Systeme Ag Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism
US6548510B1 (en) 1999-02-19 2003-04-15 Lts Lohmann Therapie Systeme Ag Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence
US20050053647A1 (en) * 1999-05-21 2005-03-10 Rudolf Matusch Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
EP2090312A1 (en) 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating attention deficit disorder
EP2087892A2 (en) 1999-07-01 2009-08-12 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating age associated learning and mental disorders
US6469227B1 (en) 1999-12-10 2002-10-22 Lectec Corporation Antipruritic patch
US20030212094A1 (en) * 2000-02-29 2003-11-13 Haruko Yamabe Novel cyclic amide derivatives
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
US8168232B2 (en) * 2000-04-26 2012-05-01 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics in cancer treatment
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20030215528A1 (en) * 2000-04-26 2003-11-20 Queens University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20110028543A1 (en) * 2000-04-26 2011-02-03 Queens University At Kingston Formulations and methods of using nitric oxide mimetics in cancer treatment
EP2002826A1 (en) 2000-11-16 2008-12-17 Euro-Celtique S.A. Titratable dosage transdermal delivery system
US20040132751A1 (en) * 2001-04-24 2004-07-08 Klaus Opitz Use of desoxypeganine for treating central nervous system symptoms resulting from intoxications by psychotrops
US20040116406A1 (en) * 2001-04-24 2004-06-17 Klaus Opitz Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
US8207159B2 (en) 2001-04-24 2012-06-26 Hf Arzneimittelforschung Gmbh Use of galanthamine for the treatment of pathological manifestations of the central nervous system based on intoxications with psychotropic substances
US20040192683A1 (en) * 2001-06-18 2004-09-30 Joachim Moormann Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments
US20040167145A1 (en) * 2001-07-12 2004-08-26 Klaus Opitz Active ingredient combination for the pharmacological therapy of nicotine dependence
US6933321B2 (en) 2002-02-15 2005-08-23 Endorecherche, Inc. Antiandrogenic biphenyls
US20040006134A1 (en) * 2002-02-15 2004-01-08 Endorecherche, Inc. Antiandrogenic biphenyls
US20030181516A1 (en) * 2002-03-19 2003-09-25 Krylov Boris Vladimirovich Substance with sedative effect
US7087640B2 (en) 2002-03-19 2006-08-08 Technology Commercialization Corp Substance with sedative effect
US20030220632A1 (en) * 2002-05-23 2003-11-27 Wolfgang Strasser Method of using gel sheets for laser treatment
US20090062781A1 (en) * 2002-05-23 2009-03-05 Ed. Geistlich Soehne Ag Fur Chemische Industrie Method of using gel sheets for laser treatment
WO2004075933A2 (en) * 2003-02-26 2004-09-10 Lavipharm S.A. Devices for releasing volatile substances and methods of producing the devices
WO2004075933A3 (en) * 2003-02-26 2005-01-13 Lavipharm Sa Devices for releasing volatile substances and methods of producing the devices
US20060199866A1 (en) * 2003-04-25 2006-09-07 Joachim Moormann Combination of desoxypeganine and mecamylanine for the treatment of alcohol abuse
US20050002997A1 (en) * 2003-04-30 2005-01-06 Howard Stephen A. Tamper resistant transdermal dosage form
US8778382B2 (en) 2003-04-30 2014-07-15 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040260253A1 (en) * 2003-06-18 2004-12-23 Rosati Coni F. Method and apparatus for supplying gas to an area
US7263814B2 (en) 2003-06-18 2007-09-04 Oxyband Technologies, Inc. Method and apparatus for supplying gas to an area
US20050251084A1 (en) * 2003-06-18 2005-11-10 Rosati Coni F Method and apparatus for supplying gas to an area
US20060200100A1 (en) * 2003-06-18 2006-09-07 Rosati Coni F Method and apparatus for supplying gas to an area
US7014630B2 (en) 2003-06-18 2006-03-21 Oxyband Technologies, Inc. Tissue dressing having gas reservoir
US20050250749A1 (en) * 2004-01-07 2005-11-10 Endorecherche, Inc. Helix 12 directed pharmaceutical products
US9090651B2 (en) 2004-01-07 2015-07-28 Endorecherche, Inc. Helix 12 directed pharmaceutical products
WO2005066194A1 (en) 2004-01-07 2005-07-21 Endorecherche, Inc. Helix 12 directed steroidal pharmaceutical products
WO2006133567A1 (en) 2005-06-17 2006-12-21 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US20100241219A1 (en) * 2005-06-20 2010-09-23 Abbeymoor Medical , Inc Medicament delivery article, accessory & system
US8455009B2 (en) 2005-09-27 2013-06-04 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8420126B2 (en) 2005-09-27 2013-04-16 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US9161954B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US9161955B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9161956B2 (en) 2005-09-27 2015-10-20 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US10632155B2 (en) 2005-09-27 2020-04-28 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9724370B2 (en) 2005-09-27 2017-08-08 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20080299087A1 (en) * 2005-09-27 2008-12-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US20070231401A1 (en) * 2005-09-27 2007-10-04 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US8182841B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9750771B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-inflammation methods
US9750772B2 (en) 2005-09-27 2017-09-05 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP2664337A1 (en) 2005-09-27 2013-11-20 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8460714B2 (en) 2005-09-27 2013-06-11 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US20070071828A1 (en) * 2005-09-27 2007-03-29 Bio-Tissue, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US10272119B2 (en) 2005-09-27 2019-04-30 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US8440235B2 (en) 2005-09-27 2013-05-14 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9198939B2 (en) 2005-09-27 2015-12-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US9956252B2 (en) 2005-09-27 2018-05-01 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
WO2007062266A2 (en) 2005-11-28 2007-05-31 Marinus Pharmaceuticals Ganaxolone formulations and methods for the making and use thereof
WO2007084266A3 (en) * 2006-01-19 2007-11-29 Dow Corning Silicone adhesive for adhesion to wet surfaces
US20080295960A1 (en) * 2006-01-19 2008-12-04 Schalau Ii Gerald Kenneth Silicone Adhesive For Adhesion To Wet Surfaces
US7914645B2 (en) 2006-01-19 2011-03-29 Dow Corning Corporation Silicone adhesive for adhesion to wet surfaces
WO2007084266A2 (en) * 2006-01-19 2007-07-26 Dow Corning Corporation Silicone adhesive for adhesion to wet surfaces
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EP2532234A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2529622A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526933A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526934A2 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2526771A1 (en) 2006-09-22 2012-11-28 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2529621A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2201840A1 (en) 2006-09-22 2010-06-30 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP2530083A1 (en) 2006-09-22 2012-12-05 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2532235A1 (en) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2443929A1 (en) 2006-09-22 2012-04-25 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
US20100143270A1 (en) * 2007-02-21 2010-06-10 University Of Louisville Research Foubdation Therapeutic cotinine compositions
WO2008109124A1 (en) * 2007-03-06 2008-09-12 Novalar Pharmaceuticals, Inc. Use of nitroglycerin to reverse local anesthesia
US9700522B2 (en) 2007-03-19 2017-07-11 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
US20090042844A1 (en) * 2007-04-12 2009-02-12 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2008124922A1 (en) 2007-04-12 2008-10-23 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009035818A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20100068708A1 (en) * 2008-05-07 2010-03-18 Wintherix Llc Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells
WO2010027875A2 (en) 2008-08-27 2010-03-11 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
EP3178480A1 (en) 2009-06-16 2017-06-14 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US11452731B2 (en) 2009-06-16 2022-09-27 Endorecherche, Inc. Method of treating and preventing loss of cognition
EP3682880A1 (en) 2009-06-16 2020-07-22 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US10342805B2 (en) 2009-06-16 2019-07-09 Endorecherche, Inc. Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
EP2650294A1 (en) 2009-10-12 2013-10-16 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US8992491B2 (en) * 2010-01-14 2015-03-31 Laboratoires Urgo Wound dressing including agglomerates of particles suitable for rapidly gelling or solubilizing
US20130018335A1 (en) * 2010-01-14 2013-01-17 Laboratoires Urgo Novel bandage including agglomerates of particles suitable for rapidly gelling or solubilising
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
WO2011119894A2 (en) 2010-03-24 2011-09-29 Kinagen, Inc Heterocyclic compounds useful for kinase inhibition
US9212151B2 (en) 2010-03-24 2015-12-15 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US8957216B2 (en) 2010-03-24 2015-02-17 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
US10214513B2 (en) 2010-03-24 2019-02-26 Amitech Therapeutic Solutions, Inc. Heterocyclic compounds useful for kinase inhibition
WO2011130455A1 (en) 2010-04-13 2011-10-20 Najib Babul Dermal pharmaceutical compositions of 1-methyl-2',6'-pipecoloxylidide and method of use
US11607407B2 (en) 2010-04-13 2023-03-21 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
WO2011139489A2 (en) 2010-04-27 2011-11-10 Calcimedica Inc. Compounds that modulate intracellular calcium
WO2011139765A2 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2011143152A2 (en) 2010-05-11 2011-11-17 Questcor Pharmaceuticals Acth for treatment of amyotrophic lateral sclerosis
WO2011153514A2 (en) 2010-06-03 2011-12-08 Pharmacyclics, Inc. The use of inhibitors of bruton's tyrosine kinase (btk)
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US10336738B2 (en) 2010-08-27 2019-07-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9550822B2 (en) 2010-10-25 2017-01-24 Questcor Pharmaceuticals, Inc. ACTH prophylactic treatment of renal disorders
US10286041B2 (en) 2010-10-25 2019-05-14 Mallinckrodt Ard Ip Limited ACTH prophylactic treatment of renal disorders
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US8778315B2 (en) 2011-01-07 2014-07-15 Allergan, Inc. Melanin modification compositions and methods of use
US9044404B2 (en) 2011-01-07 2015-06-02 Allergan, Inc. Melanin modification compositions and methods of use
US8236288B2 (en) 2011-01-07 2012-08-07 Skinmedica, Inc. Melanin modification compositions and methods of use
WO2012094638A1 (en) 2011-01-07 2012-07-12 Skinmedica, Inc. Melanin modification compositions and methods of use
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9675733B2 (en) 2011-04-28 2017-06-13 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US10426731B2 (en) 2011-06-10 2019-10-01 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
DE102013107024A1 (en) 2011-11-15 2014-05-15 Golden Biotechnology Corporation Methods and compositions for treating, modifying, and managing bone cancer pain
US9273051B2 (en) 2011-12-30 2016-03-01 Pharmacyclics Llc Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DE102013107025A1 (en) 2011-12-30 2014-07-03 Golden Biotechnology Corporation METHODS AND COMPOSITIONS FOR THE MANAGEMENT OF DIABETIS
DE102013202928A1 (en) 2012-02-23 2013-08-29 Golden Biotechnology Corporation Methods and compositions for treating cancer metastasis
WO2013148701A1 (en) 2012-03-26 2013-10-03 Golden Biotechnology Corporation Methods and compositions for treating arteriosclerotic vascular diseases
US10040821B2 (en) 2012-07-11 2018-08-07 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US11518782B2 (en) 2012-07-11 2022-12-06 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10717763B2 (en) 2012-07-11 2020-07-21 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US10253065B2 (en) 2012-07-11 2019-04-09 Tissuetech, Inc. Compositions containing HC-HA/PTX3 complexes and methods of use thereof
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2014081675A1 (en) 2012-11-21 2014-05-30 Golden Biotechnology Corporation Methods and compositions for treating neurodegenerative diseases
WO2014130619A2 (en) 2013-02-20 2014-08-28 Golden Biotechnology Corporation Methods and compositions for treating leukemia
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
WO2015089634A1 (en) 2013-12-19 2015-06-25 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
US10398673B2 (en) 2014-02-10 2019-09-03 Respivant Services GmbH Mast cell stabilizers treatment for systemic disorders
US9707206B2 (en) 2014-02-10 2017-07-18 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9968586B2 (en) 2014-02-10 2018-05-15 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
US9265749B2 (en) 2014-02-10 2016-02-23 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10835512B2 (en) 2014-02-10 2020-11-17 Respivant Sciences Gmbh Methods of treating respiratory syncytial virus infections
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
US10238628B2 (en) 2014-02-10 2019-03-26 Respivant Sciences Gmbh Mast cell stabilizers treatment for systemic disorders
WO2015135061A1 (en) 2014-03-10 2015-09-17 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm
US10548903B2 (en) 2014-03-10 2020-02-04 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2015138919A1 (en) 2014-03-14 2015-09-17 The University Of North Carolina At Chapel Hill Small molecules for inhibiting male fertility
US10435418B2 (en) 2014-04-23 2019-10-08 The Research Foundation for the State University o Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9758533B2 (en) 2014-04-23 2017-09-12 The Research Foundation For The State University Of New York Rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjunction therewith
US9808491B2 (en) 2014-06-03 2017-11-07 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US11116800B2 (en) 2014-06-03 2021-09-14 Tissuetech, Inc. Compositions of morselized umbilical cord and/or amniotic membrane and methods of use thereof
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
WO2016086063A1 (en) 2014-11-25 2016-06-02 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
EP3872063A1 (en) 2014-11-25 2021-09-01 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US11590265B2 (en) 2015-02-23 2023-02-28 Biotissue Holdings Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
US11691951B2 (en) 2015-02-27 2023-07-04 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US11318169B2 (en) 2015-05-20 2022-05-03 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10391078B2 (en) 2015-08-07 2019-08-27 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10596146B2 (en) 2015-08-07 2020-03-24 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017040617A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
US11707492B2 (en) 2016-01-29 2023-07-25 Biotissue Holdings Inc. Fetal support tissue products and methods of use
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US11883381B2 (en) 2016-05-12 2024-01-30 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2017197240A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
US11464767B2 (en) 2016-05-25 2022-10-11 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
US11242323B2 (en) 2016-08-26 2022-02-08 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US10265267B2 (en) 2016-08-31 2019-04-23 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10463613B2 (en) 2016-08-31 2019-11-05 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10561635B2 (en) 2016-10-07 2020-02-18 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US10583113B2 (en) 2016-10-07 2020-03-10 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
WO2019023420A1 (en) * 2017-07-26 2019-01-31 Dubois Brian R Devices and methods for treating epistaxis
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
US10632209B2 (en) 2017-11-10 2020-04-28 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US11833210B2 (en) 2017-11-10 2023-12-05 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
US11147885B2 (en) 2017-11-10 2021-10-19 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2019094772A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
US11786602B2 (en) 2017-11-10 2023-10-17 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019113469A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
EP4155293A1 (en) 2018-06-07 2023-03-29 The Regents of The University of Michigan Prc1 inhibitors and methods of treatment therewith
WO2019236957A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
US11319302B2 (en) 2018-06-07 2022-05-03 The Regents Of The University Of Michigan PRC1 inhibitors and methods of treatment therewith
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
US11242325B2 (en) 2018-07-27 2022-02-08 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
WO2020142557A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020190890A1 (en) 2019-03-15 2020-09-24 Unicycive Therapeutics Inc. Nicorandil derivatives
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
WO2022133064A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
US12145913B2 (en) 2021-04-19 2024-11-19 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2023018825A1 (en) 2021-08-11 2023-02-16 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Also Published As

Publication number Publication date
US3742951B1 (en) 1982-11-23

Similar Documents

Publication Publication Date Title
US3742951A (en) Bandage for controlled release of vasodilators
US3598122A (en) Bandage for administering drugs
US3731683A (en) Bandage for the controlled metering of topical drugs to the skin
US3734097A (en) Therapeutic adhesive tape
FR2143564A1 (en) Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates
US4655768A (en) Bandage for sustained delivery of drugs
US4769028A (en) Pharmaceutical product, in medical bandage form
US3699963A (en) Therapeutic adhesive patch
US4573996A (en) Device for the administration of an active agent to the skin or mucosa
JP2763773B2 (en) Methods of using and manufacturing transdermal therapeutic products
JP2781579B2 (en) Active substance release device and method for producing the same
US5176915A (en) Plaster used as therapeutic system for the administration of active substances to the skin which exhibits a graduated active substance release, process for the production of the plaster and the use thereof
CA1233382A (en) Transdermal delivery system for administration of nitroglycerin
HRP930590B1 (en) Process for the production of a transdermal therapeutic system with an increased rate of flow of active substance
HUT55643A (en) Process for producing transdermal therapy system containing buprenorfin as agent
CA2153572A1 (en) Transdermal therapeutic system with galanthamine as active ingredient
ES8605160A1 (en) Percutaneous absorption type adhesive pharmaceutical preparation.
GB8512358D0 (en) Transdermal delivery system
GB1361289A (en) Bandage for administering drugs
US4765986A (en) Medicinal plaster for systemic use
ES8704740A1 (en) Controlled-release drugsystem and process for preparing it.
EP0303490A1 (en) Transdermal adminstration using benzyl alcohol
JPH0693921B2 (en) Transdermal medicinal drug with gradual drug release
CA2010225A1 (en) Therapeutic System for the Retarded and Controlled Transdermal or Transmucous Administration of Active Substances (1)
AU584025B2 (en) Bandage for sustained delivery of drugs

Legal Events

Date Code Title Description
B1 Reexamination certificate first reexamination